7 June 2018

ScreenPoint Medical, a spin-off of Radboud university medical center, has raised 4.3 million euros from Siemens Healthineers and private investors. With these funds, the company can accelerate the market introduction of its learning computer program Transpara, which automatically interprets x-rays of breasts for possible tumors.

Radboud university medical center spin-off ScreenPoint Medical develops software applications that can detect breast cancer in early stages from x-rays of breasts (mammograms). 

Automatic interpretation
ScreenPoint’s product is called Transpara. It was developed based on artificial intelligence (AI) in combination with large image databases, and its aim is to facilitate and improve the interpreting of mammograms. The performance of the AI system can be compared to that of radiologists, and a recent study demonstrates that the detection performance of radiologists improves when they use Transpara. Use of the system could also help decrease radiologists’ workload.

Lack of radiologists
“Interpreting mammograms is one of the most challenging tasks in radiology”, says Nico Karssemeijer, CEO of ScreenPoint, “and a shortage of skilled radiologists exists in many regions around the world. While breast cancer incidence continues to rise, innovative artificial intelligence solutions are needed to ensure that the high quality of screening programs can be maintained.”

Strategic collaboration
The investment of Siemens Healthineers marks the beginning of a strategic collaboration between the companies in the field of breast imaging and provides ScreenPoint with the opportunity to keep developing in the area of precision medicine. “We are very excited about the opportunity to partner with Siemens Healthineers. This partnership will enable an accelerated market introduction of Transpara.” 


Nico Karssemeijer is member of theme Women's cancers.

Related news items


Internal KWF review procedure 2020

13 June 2019

In agreement with the existing policy the research board and Radboud Center for Oncology have decided to continue with the mandatory internal review procedure for KWF grant applications.

read more

Peter van der Kraan new theme leader Inflammatory diseases

13 June 2019

It is our pleasure to introduce Peter van der Kraan from the Dept. of Rheumatology, as the new leader of our theme Inflammatory diseases. As such he will be the successor of Irma Joosten who has done an outstanding job in the last years as theme leader, for which we thank her wholeheartedly.

read more

RIHS PhD candidates visit Philips Healthcare

13 June 2019

On 7 June the RIHS PhD council organized an excursion to Philips Healthcare in Best.

read more

Intake of a reduced dose of pazopanib with food the effect on pharmacokinetics, patient safety and preference

13 June 2019

In Clinical Pharmacology & Therapeutics Floor Lubberman and colleagues showed that the intake of 600mg pazopanib with food resulted in a bioequivalent exposure and was preferred over a standard pazopanib dose without food.

read more

Developing malaria gametocytes under attack

6 June 2019

In Science Translational Medicine, researchers from the group of Teun Bousema and international colleagues have revealed previously unknown targets of natural human antibody responses that are found on the surfaces of red blood cells infected with malaria parasites.

read more

The XN-30 hematology analyzer for rapid sensitive detection of malaria a diagnostic accuracy study

6 June 2019

In BMC Medicine Annelies Post, Berenger Kaboré, Isaie Reuling and colleagues described a new method of malaria detection using whole blood: the XN-30 is a new hematology analyzer which simultaneously provides a complete blood count and quantification of malaria parasitemia, allowing rapid treatment.

read more